News Theramex's uterine fibroid drug Yselty backed for NHS use A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales.
News ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo... Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of
News NHS set for £30bn boost in spending review The NHS is said to be in line for a £30bn increase to its budget in the upcoming spending review, but some are concerned it will not be enough.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face